HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Jack A. Roth Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Roth, J. A. Search for Related Content PubMed Articles by Roth, J. A. Related Collections Related Article

Ann Thorac Surg 1999;68:348
© 1999 The Society of Thoracic Surgeons

---

Invited Commentary

^a Department of Thoracic and Cardiovascular Surgery The University of Texas M.D. Anderson Cancer Center 1515 Holcombe Blvd, Box 109 Houston, TX 77030-4095, USA

e-mail: jroth@mdanderson.org

Invited commentary

One of the most puzzling and troublesome aspects of treating patients with stage I lung cancer is the significant percentage of patients who recur following apparent complete resection of cancer detected at a relatively early stage. Clearly the biology of these tumors is different from other stage I cancers; however, our current staging tools are not precise enough to identify those patients who may well benefit from more aggressive multimodality treatment. . . . [Full Text of this Article]

Related Article

Significance of P53 and Rb protein expression in surgically treated non-small cell lung cancers

Yung-Chie Lee, Yih-Leong Chang, Shi-Ping Luh, Jang-Ming Lee, and Jin-Shing Chen
Ann. Thorac. Surg. 1999 68: 343-347. [Abstract] [Full Text] [PDF]